The American Journal of Managed Care2d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
FiercePharma2d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
pharmaphorum5d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...
The American Journal of Managed Care12d
First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Becker's Hospital Review5d
FDA approves injectable version of popular cancer drug
The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...
Fintel on MSN1d
Wolfe Research Downgrades Immunovant (IMVT)
Fintel reports that on January 3, 2025, Wolfe Research downgraded their outlook for Immunovant (NasdaqGS:IMVT) from ...
Targeted Oncology8d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Morningstar9d
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Human immunoglobulin G is administered subcutaneously at the same site within approximately 10 minutes after the subcutaneous injection of vorhyaluronidase alfa (genetical recombination).